Document is current
Any future updates will be listed below
-
Authors
Thomas, Molly Fisher https://orcid.org/0000-0002-1393-6559
Slowikowski, Kamil https://orcid.org/0000-0002-2843-6370
Manakongtreecheep, Kasidet
Sen, Pritha
Samanta, Nandini
Tantivit, Jessica https://orcid.org/0000-0002-2179-0377
Nasrallah, Mazen
Zubiri, Leyre
Smith, Neal P. https://orcid.org/0000-0003-1394-3158
Tirard, Alice
Ramesh, Swetha https://orcid.org/0000-0001-7833-165X
Arnold, Benjamin Y.
Nieman, Linda T.
Chen, Jonathan H.
Eisenhaure, Thomas
Pelka, Karin https://orcid.org/0000-0003-2856-8602
Song, Yuhui https://orcid.org/0000-0002-5087-4684
Xu, Katherine H.
Jorgji, Vjola
Pinto, Christopher J.
Sharova, Tatyana
Glasser, Rachel
Chan, PuiYee
Sullivan, Ryan J. https://orcid.org/0000-0001-5344-6645
Khalili, Hamed https://orcid.org/0000-0002-7956-6941
Juric, Dejan https://orcid.org/0000-0003-2983-7704
Boland, Genevieve M. https://orcid.org/0000-0002-7522-6173
Dougan, Michael
Hacohen, Nir https://orcid.org/0000-0002-2349-2656
Li, Bo
Reynolds, Kerry L.
Villani, Alexandra-Chloé https://orcid.org/0000-0001-7461-0408
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007191, K08DK127246)
Damon Runyon Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (DP2CA247831)
- License Information
-
More Information
Article History
Received: 6 June 2022
Accepted: 1 March 2024
First Online: 9 May 2024
Competing interests
: From 9 August 2021, B.L. is an employee of Genentech. M.D. has received consulting fees from Genentech, Partner Therapeutics, SQZ Biotech, AzurRx, Eli Lilly, Mallinckrodt Pharmaceuticals, Aditum, Foghorn Therapeutics, Palleon, Sorriso Pharmaceuticals, Generate Biomedicines, Asher Bio, Neoleukin Therapeutics, Moderna, Alloy Therapeutics, Third Rock Ventures, DE Shaw Research, Agenus and Curie Bio. M.D. is also a member of the scientific advisory board for Veravas, Monod Bio, Axxis Bio and Cerberus Therapeutics. R.J.S. is a consultant for Bristol Myers Squibb, Marengo, Merck, Novartis, Pfizer and Replimune. H.K. received research funding from Pfizer and Takeda. H.K. received consulting fees from Aditium Bio, AbbVie and Takeda. H.K. serves on the scientific advisory board of Vivante Health. D.J. reports grants and personal fees from Novartis, Genentech, Syros and Eisai. D.J. reports personal fees from Vibliome, PIC Therapeutics, Mapkure and Relay Therapeutics. D.J. reports grants from Pfizer, Amgen, InventisBio, Arvinas, Takeda, Blueprint Medicines, AstraZeneca, Ribon Therapeutics and Infinity that are outside the submitted work. G.M.B. has sponsored research agreements through her institution with Olink Proteomics, Teiko Bio, InterVenn Biosciences and Palleon Pharmaceuticals. G.M.B. served on advisory boards for Iovance, Merck, Nektar Therapeutics, Novartis and Ankyra Therapeutics. G.M.B. consults for Merck, InterVenn Biosciences, Iovance and Ankyra Therapeutics. She holds equity in Ankyra Therapeutics. K.P. is a consultant for Santa Ana Bio. N.H. holds equity in and advises Danger Bio/Related Sciences, is on the scientific advisory board of Repertoire Immune Medicines and CytoReason, owns equity in and has licensed patents to BioNTech and receives research funding from Bristol Myers Squibb and Calico Life Sciences. K.L.R. has received advisory board fees from SAGA Diagnostics and institutional research support from Bristol Myers Squibb. A.-C.V. received consulting fees from Merck and Bristol Myers Squibb. A.-C.V. has a financial interest in 10x Genomics. The company designs and manufactures gene sequencing technology for use in research, and such technology is being used in this research. A-.C.V.’s interests were reviewed by Massachusetts General Hospital and Mass General Brigham in accordance with their institutional policies. M.F.T., K.S., K.M., P.S., N.S., J.T., M.N., L.Z., N.P.S., A.T., S.R., B.Y.A., L.T.N., J.H.C., T.E., Y.S., K.H.X., V.J., C.J.P., T.S., R.G. and P.Y.C. do not have competing interests to declare.
